Sarcoma  >>  everolimus  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
everolimus / Generic mfg.
NCT00613132: Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Completed
1
78
US
Gleevec, RAD001, and Hydroxyurea, Gleevec-Imatinib-Imatinib mesylate, RAD001-Everolimus, Hydroxyurea-Droxia-Hydrea-Hydroxycarbamide
Annick Desjardins, Novartis Pharmaceuticals
Glioblastoma, Gliosarcoma
08/08
01/13
NCT00187174: Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Completed
1
41
US
Everolimus
St. Jude Children's Research Hospital, Novartis
Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue
10/08
10/08
NCT00927966: RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms

Completed
1
21
US
RAD001, CP-751,871
Suzanne George, MD, Brigham and Women's Hospital, Novartis, Pfizer
Sarcoma, Solid Tumor
01/11
01/11
NCT02071862: Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Checkmark Data from P1b trial in RCC in combination with CB-839
Feb 2018 - Feb 2018: Data from P1b trial in RCC in combination with CB-839
Completed
1
210
US
CB-839, Glutaminase Inhibitor, Pac-CB, combo CB-839 and Paclitaxel, CBE, combo CB-839 and everolimus, CB-Erl, combo CB-839 and erlotnib, CBD, combo CB-839 and docetaxel, CB-Cabo, combo CB-839 and cabozantinib
Calithera Biosciences, Inc
Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene
03/19
03/19
CodeBreak101, NCT04185883: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
12/26
12/27

Download Options